Multiomics CRO services — transcriptomics, proteomics & spatial biology
Genes. Proteins. Cells.
Get the full picture.
Explicyte designs and executes multiomics studies across tissues, cells and biofluids, combining single-cell and spatial transcriptomics, proteomics, flow cytometry and digital pathology.
Our in-house data science team integrates these readouts with study metadata to deliver interpretable datasets, integrated analyses and publication-ready figures.
End-to-end multiomics support
From study design to integrated biological interpretation
Study design & platform selection
We define the most informative combination of sample types, platforms, panels and multiplexing strategy according to your biological questions, available material, timeline and budget.
Fast & coordinated data generation
Assays are executed within a coordinated study plan, with platform-specific QC, sample traceability and harmonized study metadata across tissue, cellular and liquid-sample readouts.
Integrated bioinformatics & interpretation
Our in-house data science team processes, integrates and interprets multi-platform datasets, connecting molecular and cellular readouts with biological or clinical metadata to deliver study-ready results.
Multiomics CRO services for tissues, cells, and biofluids
Blending technologies around your needs
fresh frozen and FFPE tissues
Spatial biology services
FIXED CELLS, TISSUE HOMOGENATES, BIOFLUIDS
Cellular & molecular profiling
Inside our lab
Single-cell & spatial transcriptomics at Explicyte
See how our team combines 10x Genomics workflows, pathology expertise and in-house bioinformatics to generate single-cell and spatial transcriptomic datasets from research samples.
Our datasets were recently published in
Sponsor stories
Multiomics projects in practice
Paul Marteau, PharmD (study director), Imane Nafia, PhD (CSO), Loïc Cerf, MSc (COO), Alban Bessede, PhD (founder, CEO), Jean-Philippe Guégan, PhD (CTO)
Contact our team
Discuss your multiomics project and request a quote
Within 3 days, our team will arrange an online discussion to help you define the right platform, multiplexing strategy, and data analysis workflow for your study.
Answers about transcriptomics & multiomics CRO services
Frequently asked questions
What multiomics services does Explicyte provide?
Explicyte provides multiomics CRO services combining single-cell and spatial transcriptomics, proteomics, flow cytometry and digital pathology. We support study design, data generation, platform-specific quality control, bioinformatics and integrated biological interpretation across tissues, cells and biofluids.
Can Explicyte combine several omics technologies within the same study?
Yes. Multiomics studies can combine complementary molecular, cellular and spatial readouts according to the biological question and available samples. Our team helps define the most informative combination of platforms and then integrates the resulting datasets with study metadata to provide a coherent biological interpretation.
Which sample types can you analyze?
Depending on the selected platform, we can work with fresh, cryopreserved and FFPE tissues, fixed and cryopreserved cells, cell pellets, tissue homogenates and biofluids. Sample requirements, storage conditions and shipping recommendations are defined during study setup to preserve material quality and ensure compatibility with downstream assays.
How do you select the most appropriate platforms for a multiomics study?
We start from the biological questions, sample type and quality, available material, desired resolution, study size, timeline and budget. From these elements, we recommend the most informative platform or combination of platforms, together with the appropriate panel, multiplexing strategy and analysis plan.
Do you support both industry and academic multiomics projects?
Yes. Explicyte works with biotech and pharmaceutical sponsors as well as academic and medical research teams. Industry projects can support discovery, preclinical and translational programs, while academic studies can include data generation, analysis and publication-oriented deliverables.
Can Explicyte analyze existing datasets as well as generate new data?
Yes. Data-analysis projects can be scoped independently or combined with newly generated datasets, depending on the available raw data, metadata and study objectives. Our data science team can support quality control, data processing, integration, visualization and biological interpretation.
How are large multiomics datasets transferred and secured?
We adapt data transfer and storage to the client’s specific needs and IT requirements. Data can either be securely pushed to the client’s own server or hosted internally in a protected environment with controlled, secure access. At the end of the study, all relevant outputs remain securely accessible, including raw files, quality control outputs, interactive HTML reports, and vector-format figures.
What turnaround time should we expect for data analysis?
Our typical turnaround time for data analysis ranges from 1 to 4 weeks, depending on the scope and depth of analysis. Full custom analysis reports, including quality control, data cleaning, and integration with additional metadata, are typically delivered within one month for standard experiment.
Do you provide publication-ready deliverables?
Yes. For the past 10 years, we have supported academic and industry teams in the preparation of manuscripts, posters, and scientific communication materials. Our datasets have supported publications in leading journals, including Nature Medicine, Immunity, and Cancer Cell. Depending on the project scope, we deliver publication-ready figures, integrated analysis outputs, and Materials and Methods content.
How does Explicyte Multiomics usually work from a business and IP perspective?
Our projects are typically structured as fee-for-service engagements, with scope, deliverables, timelines, and usage rights defined contractually upfront. Unless otherwise agreed, clients retain full intellectual property rights to their datasets and project results, while Explicyte retains ownership of its proprietary methods and workflows.
